Taysha Corp (TSHA) - Amount of Cash per Share

Corporate emblem and logo of Taysha Gene Therapies (TSHA)

Taysha Gene Therapies is currently focusing on one primary drug candidate while seeking a strategic partner for survival. The liquid position per share trend on the GURU.Markets chart shows that 1.31 serves as the base value of the parameter. Viral vector patents and orphan drug designations provide a defensive moat, while strict FDA oversight and high dose production costs remain significant barriers.

TSHA Taysha Gene Therapies Inc: Cash Funds per Share in the range 07/04/2022 - 11/21/2026

Analytical breakdowns for Taysha Gene Therapies

- share price and consensus valuation forecast:
Summary company analysis:Taysha Gene Therapies
Core merchandise of Taysha Corp

Assessing the operational strength of an asset requires an analysis of the liquid reserves per common share, which determines the actual cash support for each security. For Taysha Gene Therapies (TSHA), which is developing a closed-loop CNS gene therapy circuit, the cash per share metric reflects the ability to fund costly AAV vector development without incurring debt, confirming the fundamental stability of the business.

Key competitors

TEM (Tempus AI Inc) - Cash Calculated per Single Share|Cash per Share QGEN|IONS - Cash on Hand per Share|Cash Funds per Share Repligen RGEN|RNA: Cash Funds per Single Share|CRSP: Cash per Single Share|GeneDx Corp (WGS) - Cash per Single Share|RARE: Cash per Share|BEAM - Cash Funds Calculated per Share|SRPT (Sarepta Therapeutics) - Cash per Share|Cash per Single Share Twist Bioscience Inc (TWST)|Cash per Share TXG|Cash Funds Calculated per Share Intellia|Stoke - Cash per Single Share|BLFS: Cash Funds per Single Share|Wave Life Sciences Corp - Cash per Share|Maze Therapeutics, Inc. (MAZE) - Cash per Single Share|Sionna Therapeutics Inc (SION) - Cash Funds per Share|Cash per Single Share Prime Medicine Corp|Cash Funds per Share uniQure Pharma|MGTX - Cash Funds Volume per Share|Cash per Share RGNX|Cash Funds per Share SLDB (Solid Biosciences)|Ocugen Corp - Cash per Single Share|PACB: Cash Funds per Single Share|benitec.com - Cash per Share|DSGN - Cash per Share|RCKT: Cash per Share|FDMT (4D Molecular Therapeutics Inc) - Cash Funds per Share|Cash per Single Share LXEO|Cash Funds per Share KRRO|Cash per Share EDIT|SLN - Cash on Hand per Share|Cash per Share PRQR (ProQR)|CDXS - Cash per Single Share|Sangamo Therapeutics Inc. - Cash per Share|NAUT - Cash per Share|MGX: Cash per Share|Cash per Single Share Precision BioSciences, Inc.|GBIO (Generation Bio) - Cash per Share|Boundless Bio Inc. (BOLD) - Cash Funds Calculated per Share|Cash per Single Share XCUR (exicuretx.com)|Imunon Inc - Cash Funds per Single Share|Cash per Share PHIO (Phio Pharmaceuticals Corp)|Amount of Cash per Share MBIO|RNAZ - Cash Funds per Share|Amount of Cash per Share BNGO (bionanogenomics.com)|Applied DNA Sciences (APDN) - Cash Funds per Share|Bluebird Bio - Amount of Cash per Share|IPA (ImmunoPrecise Antibodies Ltd) - Cash per Share|Cash on Hand per Share Omega Therapeutics, Inc. OMGA|Cash per Share OMIC|RGLS (Regulus Therapeutics Inc.) - Amount of Cash per Share|Cash per Share SYRS (Syros Pharmaceuticals Inc.)|Cash Calculated per Single Share TBIO (Codex DNA)|TCON - Cash Funds per Share|Cash on Hand per Share Unity Biotechnology